Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Visionstate Announces Deals in Canada and the US, Highlights Growing Opportunities (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Akero Therapeutics Inc AKRO

Healthcare Biotechnology
Akero Therapeutics, Inc. is a clinical-stage company. The Company is developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including metabolic dysfunction-associated steatohepatitis (MASH), a disease without any approved therapies. Efruxifermin (EFX), is its lead product candidate for MASH, which is being evaluated in the ongoing... see more

NDAQ:AKRO - Post Discussion

Akero Therapeutics Inc > Akero Therapeutics Reports Positive Phase 2b HARMONY Study D
View:
Post by whytestocks on Mar 04, 2024 1:15pm

Akero Therapeutics Reports Positive Phase 2b HARMONY Study D

NEWS: $AKRO Akero Therapeutics Reports Positive Phase 2b HARMONY Study Data2024-03-04 07:22:02 ET DENVER, Colo., Mar 04, 2024 ( 247marketnews.com )- Akero Therapeutics, Inc. (NASDAQ: AKRO ) released, this morning, its preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxife...AKRO - Akero Therapeutics Reports Positive Phase 2b HARMONY Study Data
Be the first to comment on this post
Akero Therapeutics Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities